Literature DB >> 9626476

Differential permeability of a human brain tumor xenograft in the nude rat: impact of tumor size and method of administration on optimizing delivery of biologically diverse agents.

E A Neuwelt1, P A Barnett, C I McCormick, L G Remsen, R A Kroll, G Sexton.   

Abstract

To assess how to maximize drug delivery to intracerebral tumors and surrounding brain, this study examined the effects of route and method of administration and tumor size on the distribution of three agents in a nude rat intracerebral tumor xenograft model. Aminoisobutyric acid (M(r) 103), methotrexate (M(r) 454), and dextran 70 (M(r) 70,000) were administered i.v. or intra-arterially (i.a.) with or without osmotic blood-brain barrier disruption (BBBD) at 8, 12, or 16 days after tumor cell inoculation (n = 72). A 2.2- to 2.5-fold increase in delivery to tumor and surrounding brain was observed when i.a. was compared with i.v., and a 2.5- to 7.6-fold increase was observed when BBBD was compared with the saline control. The combined effect of i.a. administration and BBBD was to increase delivery 6.3-16.7-fold. The greatest benefit of BBBD was seen in animals with 8-day tumors, whereas BBBD had less benefit in improving delivery to intracerebral tumor and brain around tumor as the tumors grew larger. Regional delivery decreased as the molecular weight of the agent increased. Based on these results, we suggest that i.a. administration of antitumor agents may be adequate to obtain initial responses in large, very permeable, intracerebral tumors. However, in smaller, less permeable tumors or after an initial response to treatment, there may be a significant therapeutic advantage to i.a. agent administration and BBBD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9626476

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

Review 1.  Recent advances in blood-brain barrier disruption as a CNS delivery strategy.

Authors:  Marc-André Bellavance; Marie Blanchette; David Fortin
Journal:  AAPS J       Date:  2008-03-18       Impact factor: 4.009

Review 2.  Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going.

Authors:  Randy S D'Amico; Deepak Khatri; Noah Reichman; Nitesh V Patel; Tamika Wong; Sherese R Fralin; Mona Li; Jason A Ellis; Rafael Ortiz; David J Langer; John A Boockvar
Journal:  J Neurooncol       Date:  2020-02-19       Impact factor: 4.130

3.  Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.

Authors:  Daniel J Guillaume; Nancy D Doolittle; Seymur Gahramanov; Nancy A Hedrick; Johnny B Delashaw; Edward A Neuwelt
Journal:  Neurosurgery       Date:  2010-01       Impact factor: 4.654

4.  Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system.

Authors:  Juyoun Jin; Kyeung Min Joo; Yoonhee Nam; Dae Hyun Kim; Se Jeong Lee; Mi-Young Jo; Younggeon Jin; Hyeong-Seok Kim; Soo Won Seo; Seok Jin Kim; DO-Hyun Nam; Won Seog Kim
Journal:  Exp Ther Med       Date:  2010-08-26       Impact factor: 2.447

5.  Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.

Authors:  Leslie L Muldoon; Seth J Lewin; Edit Dósa; Dale F Kraemer; Michael A Pagel; Nancy D Doolittle; Edward A Neuwelt
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

6.  Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13.

Authors:  Edward Rustamzadeh; Daniel A Vallera; Deborah A Todhunter; Walter C Low; Angela Panoskaltsis-Mortari; Walter A Hall
Journal:  J Neurooncol       Date:  2006-05       Impact factor: 4.130

7.  Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries.

Authors:  Bernhard Erdlenbruch; Mehrnaz Alipour; Gert Fricker; David S Miller; Wilfried Kugler; Hansjörg Eibl; Max Lakomek
Journal:  Br J Pharmacol       Date:  2003-11-03       Impact factor: 8.739

8.  Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma.

Authors:  Kristoph Jahnke; Leslie L Muldoon; Csanad G Varallyay; Seth J Lewin; Robert D Brown; Dale F Kraemer; Carole Soussain; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2009-01-21       Impact factor: 12.300

Review 9.  Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances.

Authors:  Nancy D Doolittle; Leslie L Muldoon; Aliana Y Culp; Edward A Neuwelt
Journal:  Adv Pharmacol       Date:  2014-08-22

10.  BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models.

Authors:  Leslie L Muldoon; Edward A Neuwelt
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.